Merck, Lycera broaden partnership on autoimmune disease drugs

Merck & Co. expanded a collaboration with Lycera to develop and market small-molecule drugs against autoimmune diseases. The deal entitles Lycera to an undisclosed upfront fee and research support plus more than $300 million in possible milestone fees, plus royalties. Merck will handle clinical development, and will get the global rights to marketing.

View Full Article in:

Genetic Engineering & Biotechnology News · Crain's Detroit Business (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN